汉森制药(002412) - 2025 Q1 - 季度财报

Revenue and Profit - The company's revenue for Q1 2025 was ¥269,286,565.75, representing a 6.00% increase compared to ¥254,032,546.62 in the same period last year[4] - Net profit attributable to shareholders decreased by 80.68% to ¥11,257,164.35 from ¥58,264,674.17 year-on-year[4] - Basic and diluted earnings per share dropped by 80.66% to ¥0.0224 from ¥0.1158 year-on-year[4] - Net profit for the current period was ¥11,257,164.35, a significant decrease of 80.7% from ¥58,264,674.17 in the previous period[20] - Other comprehensive income after tax for the current period was -¥21,337,283.83, compared to ¥6,133,860.08 in the previous period[20] - The total comprehensive income for the current period was -¥10,080,119.48, a decrease from ¥64,398,534.25 in the previous period[20] Cash Flow - The net cash flow from operating activities increased by 140.97% to ¥49,407,081.75, up from ¥20,503,807.95 in the previous year[4] - Operating cash flow for the current period is ¥49,407,081.75, a significant increase from ¥20,503,807.95 in the previous period, reflecting a growth of approximately 141.5%[21] - Total cash inflow from investment activities is ¥297,965,601.16, compared to ¥185,560,117.38 in the previous period, indicating an increase of about 60.5%[21] - Cash outflow for investment activities reached ¥386,746,011.20, up from ¥184,230,522.44, resulting in a net cash flow from investment activities of -¥88,780,410.04, compared to a positive ¥1,329,594.94 previously[21] - The company reported a decrease in cash flow from financing activities, with a net cash flow of -¥360,475.00 compared to a positive ¥1,831,534.64 in the previous period[22] - Cash and cash equivalents at the end of the period stand at ¥86,814,834.11, an increase from ¥74,792,141.37 in the previous period[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,546,113,612.79, a slight decrease of 0.04% from ¥2,547,234,247.32 at the end of the previous year[4] - Total liabilities increased to ¥352,811,672.12 from ¥343,852,187.17, marking a rise of 2.8%[18] - The company's total equity attributable to shareholders decreased by 0.46% to ¥2,193,301,940.67 from ¥2,203,382,060.15 at the end of the previous year[4] - Long-term equity investments decreased from ¥855,753,806.92 to ¥787,701,027.88, a reduction of approximately 7.9%[16] - Total current assets increased from ¥1,123,168,939.47 to ¥1,199,045,999.11, reflecting a growth of about 6.8%[16] Expenses - Management expenses increased by 56.21% to ¥19,155,983.25, attributed to higher costs related to annual meetings and business hospitality[8] - Research and development expenses for the current period were ¥9,330,205.66, compared to ¥7,885,856.79, indicating a growth of 18.3%[19] - Total operating costs amounted to ¥201,370,449.78, up from ¥193,715,774.24, reflecting a rise of 3.4%[19] - The company experienced a 341.89% increase in other operating expenses, totaling ¥466,337.46, primarily due to the write-off of biological assets[9] Shareholder Information - Hainan Hansen Holdings holds 42.13% of the shares, making it the controlling shareholder of the company[13] - The number of shares held by the top ten shareholders includes significant stakes from Hainan Hansen Holdings and Shanghai Fosun Pharmaceutical, with the latter holding 4.82%[13] - The company has a total of 212,006,189 shares held by Hainan Hansen Holdings, which are unrestricted[13] Inventory and Receivables - Inventory decreased from ¥222,876,023.84 to ¥212,211,507.99, a decline of about 4.8%[16] - The company reported accounts receivable increased from ¥287,184,352.67 to ¥339,164,828.32, an increase of approximately 18.1%[16] - The total amount of other current assets decreased from ¥80,872,548.44 to ¥76,139,117.21, a decline of about 5.4%[16] Other Information - The company has not yet audited the first quarter report, indicating that the figures may be subject to change[23] - The company will implement new accounting standards starting in 2025, which may affect future financial reporting[24]